



HAL
open science

Microglia mitigate neuronal activation in a zebrafish model of Dravet syndrome

Alexandre Brenet, Julie Somkhit, Zsolt Csaba, Sorana Ciura, Edor Kabashi, Constantin Yanicostas, Nadia Soussi-Yanicostas

► **To cite this version:**

Alexandre Brenet, Julie Somkhit, Zsolt Csaba, Sorana Ciura, Edor Kabashi, et al.. Microglia mitigate neuronal activation in a zebrafish model of Dravet syndrome. 2023. hal-04750420v4

HAL Id: hal-04750420

<https://hal.science/hal-04750420v4>

Preprint submitted on 5 Jun 2023 (v4), last revised 23 Oct 2024 (v5)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

17 **Running title:** microglia remodeling in epilepsy

18 **Abstract**

19 It has been known for a long time that epileptic seizures induce brain neuroinflammation
20 through microglia activation. Nevertheless, these cells have not yet received the attention they
21 deserve in epilepsy research and the consequences of this microglial response on subsequent
22 neuronal activity remain poorly understood. Here, we sought to fill this gap and gain a larger
23 understanding of the role of microglia in the pathophysiology of epilepsy, using an established
24 zebrafish Dravet syndrome epilepsy model based on *Scn1Lab* sodium channel loss-of-
25 function, combined with live microglia and neuronal Ca^{2+} imaging, local field potential (LFP)
26 recording and genetic microglial ablation. First, in *scn1Lab*-deficient larvae experiencing
27 epileptiform seizures, microglia displayed morphological and biochemical features suggesting
28 M1-like pro-inflammatory activation, including reduced branching, amoeboid-like morphology,
29 and a marked increase in the number of microglia expressing pro-inflammatory cytokine $Il1\beta$.
30 More importantly, *scn1Lab*-KD larvae fully lacking microglia showed a significantly increased
31 neuronal activation compared to that seen in *scn1Lab*-KD individuals with microglia, as shown
32 by LFP recording and Ca^{2+} imaging, and also by the epileptiform seizure-related whirling
33 swimming of larvae. These findings are evidence that despite a microglial activation and the
34 synthesis of pro-inflammatory cytokines, microglia provide neuroprotection to epileptic
35 neuronal networks, making these cells a promising therapeutic target in epilepsy.

36

37 Introduction

38 Epilepsy is the most frequent neurological disorder, affecting more than 1% of the world's
39 population (Fisher *et al.*, 2014; Fisher, 2015). The disease is characterized by recurrent
40 seizures caused by synchronized hyperactivation of neuronal networks of various sizes
41 ranging from a limited brain region to the whole cortex, leading to focal or generalized seizures,
42 respectively (Thurman *et al.*, 2011; Stafstrom and Carmant, 2015; World Health Organization,
43 2019). Potent anti-epileptic drugs (AEDs) have been developed over the last decades.
44 However, they are ineffective in approximately one-third of patients, especially children with
45 developmental epileptic encephalopathies, such as Dravet syndrome (DS) (Brunklaus, Dorris
46 and Zuberi, 2011; Kwan, Schachter and Brodie, 2011; Wu *et al.*, 2015). In addition, they can
47 cause significant side effects, such as teratogenicity in pregnant women (Xue-Ping *et al.*, 2019;
48 Marxer *et al.*, 2021). These limitations emphasize the need for novel anti-epileptic strategies.
49 Notably, most existing AEDs are “neurocentric”, targeting neuronal proteins directly involved
50 in neuronal network activation. At the same time, microglia have so far received little attention
51 as a therapeutic target in epilepsy despite large amounts of data accumulated over the last
52 decades, strongly suggesting that these cells are essential players in the pathophysiology of
53 the disease (Vezzani, Balosso and Ravizza, 2019).

54 Microglial cells, the resident brain macrophages, have several essential functions, including
55 immunoprotection, maintenance of neuron health and homeostasis, and maturation of
56 neuronal networks through developmentally controlled apoptosis of supernumerary neurons
57 and pruning excess synapses (Lukens and Eyo, 2022). As immune cells, microglia also
58 respond rapidly to brain injury or infection through complex reprogramming, referred to as
59 microglia activation, which comprises morphological and biochemical changes, including the
60 synthesis and release of pro-inflammatory cytokines (Woodburn, Bollinger and Wohleb, 2021).
61 In epileptic patients, it has long been known that seizures cause the activation of microglial
62 cells and synthesis of inflammatory mediators (Ravizza *et al.*, 2008; Vezzani *et al.*, 2008;
63 Vezzani, 2013; Vezzani, Balosso and Ravizza, 2019). Analysis of post-mortem brain tissues
64 from epileptic patients has indeed shown massive microglial activation, directly correlated with
65 seizure severity (Boer *et al.*, 2008; Morin-Brureau *et al.*, 2018). Moreover, in various
66 pharmacological rodent epilepsy models, pronounced morphological changes of microglia
67 were rapidly observed after seizures, prior to the onset of neuronal damage (Eyo *et al.*, 2014;
68 Avignone *et al.*, 2015). However, other studies have highlighted the wide variability of
69 inflammatory responses observed in patients and animal epilepsy models (Gasmi *et al.*, 2021).
70 Some data suggest that microglia may be harmful in an epileptic context, probably owing to
71 the release of pro-inflammatory cytokines, known to be pro-epileptogenic factors (Vezzani *et al.*,
72 1999; Rana and Musto, 2018; Andoh, Ikegaya and Koyama, 2019). Conversely, other

73 studies suggest that microglia may play a beneficial role in epilepsy by decreasing the activity
74 of neuronal networks (Li, X. Du, *et al.*, 2012; Vinet *et al.*, 2012; Eyo *et al.*, 2014; Badimon *et*
75 *al.*, 2020). Data also suggest that the response of microglia to epileptic seizures is not uniform
76 throughout the brain, with cells showing a wide range of phenotypes within the same individual
77 (Morin-Brureau *et al.*, 2018). Moreover, the levels of both pro-inflammatory and anti-
78 inflammatory cytokines are increased in microglia after epileptic seizures, supporting the notion
79 that the response of these cells to seizures is not limited to classic M1-type pro-inflammatory
80 activation, thus highlighting the complexity of this microglial response (Benson *et al.*, 2015).
81 Whether microglia activity has an overall detrimental or beneficial role in epilepsy is still a
82 largely open question with far-reaching therapeutic implications (Lukens and Eyo, 2022).

83 To address this issue and gain a better understanding of the role of microglia in epilepsy,
84 we used a zebrafish model of Dravet syndrome (DS), a severe intractable epileptic syndrome
85 in infants caused in 70–80% of cases by *de novo* mutations in the gene encoding the voltage-
86 gated sodium channel, *SCN1A* (Claes *et al.*, 2001; Dravet, 2011). We used this zebrafish
87 epilepsy model to investigate the morphology and dynamic behavior of microglial cells *in vivo*,
88 using the Tg[mpeg1:mCherryF] line, which enables imaging of microglial cells in living
89 zebrafish embryos and larvae combined with neuronal Ca²⁺ imaging, local field potential (LFP)
90 recording and genetic microglia ablation.

91 We found that microglia were deeply remodeled in *scn1Lab*-deficient larvae, with
92 morphology shifted toward the amoeboid and less branched phenotype, combined with a
93 markedly increased mobility of their cell bodies and an increased number of I11β-expressing
94 cells. In addition, in microglia-depleted *scn1Lab*-deficient larvae, neuronal hyperactivation was
95 significantly increased compared with their siblings with microglia, suggesting that activities of
96 these cells lent neuroprotection to epileptic neurons and decreased their activity.


97 Results

98 Microglia morphological changes in *scn1Lab*-KD larvae

99 To increase our understanding of microglia phenotypes in epileptic brains *in vivo*, we first
100 made use of the live imaging techniques available in zebrafish, especially real-time microglia
101 imaging (Hassan-Abdi *et al.*, 2019), combined with two zebrafish *scn1Lab* models of Dravet
102 syndrome epilepsy, *scn1Lab* morphant (Brenet *et al.*, 2019) and *scn1Lab*^{s552/s552} mutant larvae
103 (Scott C Baraban, Dinday and Hortopan, 2013). Both models show recurrent spontaneous
104 epileptiform seizures at 4 days post-fertilization (dpf), as visualized by LFP recording and Ca²⁺
105 imaging and by the characteristic swirling behavior of the larvae (Scott C. Baraban, Dinday
106 and Hortopan, 2013; Zhang *et al.*, 2015; Brenet *et al.*, 2019). Specifically, we mainly used
107 *scn1Lab* morphants, referred to below as *scn1Lab*-KD individuals, and verified that the results
108 were identical in *scn1Lab*^{s552/s552} mutants, displaying a complete loss of Scn1Lab function
109 (Scott C. Baraban, Dinday and Hortopan, 2013; Brenet *et al.*, 2019). To visualize microglial
110 cells *in vivo*, we chose the transgenic Tg[*mpeg1*:mCherryF] line, which shows intense labeling
111 of these cells (Travnickova *et al.*, 2015). However, as this transgenic line expresses mCherryF
112 in both microglia and macrophages, we verified that all the microglia imaged in this study also
113 expressed the Tg[p2y12:P2Y12-GFP] transgene (Sieger *et al.*, 2012), as P2RY12 is a specific
114 marker of microglial cells (Mildner, 2017).

115 As previously shown (Peri and Nüsslein-Volhard, 2008; Hassan-Abdi *et al.*, 2019), in wild-type
116 (WT) larvae, microglia displayed the characteristic branched morphology of "resting" microglia,
117 with a relatively small cell body and several long and ramified processes (**Figure 1A; 1A1-3**
118 **and Supp. Fig. 1A₂ (Video 1):** <https://urlz.fr/iPxZ>). By contrast, in *scn1Lab*-KD larvae,
119 microglia exhibited a more rounded morphology, with a larger cell body combined with fewer
120 and shorter branches (**Figure 1B; 1B1-3 and Supp. Fig. 1B₃ (Video 2):** <https://urlz.fr/iPxP>).
121 To further characterize the morphological differences in the two genetic contexts, we used the
122 3D image analysis software Imaris (Bitplane) to measure several microglial cell morphological
123 parameters (sphericity, volume, surface area, branch number, branch length and ramification
124 index). Data confirmed that microglia in *scn1Lab*-KD larvae displayed an increased sphericity
125 (WT: 0.567 ± 0.006 vs. *scn1Lab*-KD: 0.644 ± 0.006; $p < 0.0001$) (**Figure 1C**), a decreased
126 number of branches (WT: 6.3 ± 0.2 vs. *scn1Lab*-KD: 5.1 ± 0.2; $p < 0.0001$) (**Figure 1D**), a
127 decreased total (WT: 115 ± 3 μm vs. *scn1Lab*-KD: 85 ± 3 μm; $p < 0.0001$) (**Figure 1E**) and
128 mean processes length (control: 23.5 ± 0.4 μm vs. *scn1Lab*-KD: 19.6 ± 0.3 μm; $p < 0.0001$)
129 (**Figure 1F**), and a decreased ramification index (WT: 1.94 ± 0.05 vs. *scn1Lab*-KD: 1.74 ±
130 0.05; $p < 0.0001$) (**Figure 1G**) compared with microglia in WT individuals. Sholl analysis, a
131 method used to quantify both the extent and complexity of cell branches (Imaris software),
132 further confirmed that microglia in *scn1Lab*-KD individuals had fewer and shorter branches

133 than their WT siblings (**Figure 1H**). Taken together, our data show that microglia exhibited an
 134 amoeboid-like morphology reminiscent of that of M1-type activated macrophages in *scn1Lab*-
 135 KD larvae.



136


137 **Figure 1: Microglial morphology in the *scn1Lab* model.**

138 (A-B) Dorsal view of 4 dpf Tg[mpeg1:mCherryF] control (A₁) and *scn1Lab*-KD (B₂) larvae optic
139 tectum showing microglial cell population, as well as 3D reconstruction of control (A₂-A₃) and
140 *scn1Lab*-KD (B₂-B₃) microglia. (C-G) Quantification of microglial cells' sphericity (C), number
141 of processes (D), total processes length (E), mean processes length (F) and ramification index
142 (G) in 4 dpf *scn1Lab*-KD larvae ($N = 11$; $n = 239$) compared to sibling controls ($N = 11$; $n =$
143 228). (H) Sholl analysis of control (grey) and *scn1Lab*-KD (blue) microglia. (I) Diagram of the
144 head of a zebrafish larva with the area of interest (the periventricular stratum) framed in red.
145 (J) Cluster analysis of the microglial population of 4 dpf *scn1Lab*-KD ($N = 11$; $n = 239$) and
146 sibling control ($N = 11$; $n = 228$) based on sphericity (S), number of processes (NP), total
147 processes length (TL), area (A), and volume (V), leading to three microglial populations. (K)
148 Repartition of the control (white) and *scn1Lab*-KD (blue) microglial population in the three
149 clusters produced before. All images were acquired with SP8 Leica scanning laser confocal
150 equipped with 20x/multi-immersion 0.75 objective. All data are represented as the mean \pm
151 sem. p -values were determined using Mann-Whitney or unpaired Student t -test depending on
152 the normal distribution of the values. n.s., non-significant; **, $p < 0.01$; ***, $p < 0.001$; ****, $p <$
153 0.0001. Scale bars: 50 μm (A₁, B₁); 10 μm (A₂, A₃, B₂, B₃).

154 To better evaluate the extent of microglia morphological differences in *scn1Lab*-KD and WT
155 larvae, we performed a cluster analysis of these cells in the two genetic contexts based on the
156 five morphological parameters showing significant changes as indicated above (sphericity,
157 branch number, branch length, surface area, and volume) (see Materials and Methods). The
158 first population comprised cells showing low sphericity, numerous elongated branches, and
159 high surface area and volume, referred to below as "branched" microglia. The second
160 comprised microglia displaying high sphericity, few short processes, and low surface area and
161 volume, referred to below as "amoeboid" cells. The third comprised cells with intermediate
162 characteristics, referred to below as "transitional" microglia (Figure 1J). Although the three
163 populations of microglia were found in both contexts, their respective proportion varied
164 considerably. In *scn1Lab*-KD larvae, we observed a significant increase in the percentage of
165 "amoeboid" microglia (29.1 ± 1.2 vs. $10.4 \pm 0.3\%$; $p < 0.001$) combined with a significant
166 decrease in the percentage of "branched" microglia (10.2 ± 0.8 vs. $27.8 \pm 1.5\%$; $p < 0.01$)
167 (Figure 1K). These findings further prove that microglia display an M1-like reactive phenotype
168 in *scn1Lab*-KD larvae.

169 Visual examination of the behavior of microglia in *scn1Lab*-KD and WT larvae provided a first
170 indication that these cells displayed an increased mobility in the mutant context. To confirm
171 this observation, we measured the speed of microglia cell bodies in the two genetic contexts.
172 In WT larvae, as previously described (Hassan-Abdi *et al.*, 2019), microglia had several
173 branches that were constantly extending and retracting, while their cell bodies remained almost

174 immobile (Figure 2A₁-A₂, 2C₁, 2F₁) (Supp. Video 3, <https://urlz.fr/iOlz>). By contrast, cell
 175 bodies of *scn1Lab*-KD microglia were much more mobile (Figure 2B₁-B₂, 2C₂, 2F₂) (Supp.
 176 Video 4, <https://urlz.fr/iOIA>).




177
 178 **Figure 2: Microglial dynamics in the *scn1Lab* model.**

179 (A) Confocal time-lapse showing microglial dynamic in a 4 dpf Tg[mpeg1:mCherryF] control
 180 living larval brain. (B) Confocal time-lapse showing microglial dynamic in a 4 dpf
 181 Tg[mpeg1:mCherryF] *scn1Lab*-KD living larval brain. (C) Merged image of two-time points
 182 highlighting the increase in microglial soma displacement in *scn1Lab*-KD larvae (C₂) compared
 183 to sibling control (C₁) (0': cyan, 36': magenta, merge: white). (D-E) Quantification of microglial
 184 cell body displacement (D) and mean displacement speed (E) over 60' recording in 4 dpf
 185 *scn1Lab*-KD larvae ($N = 6$; $n = 55$) compared to sibling controls ($N = 4$; $n = 46$). (F) Microglial
 186 cell tracking over 60' in 4 dpf control (F₁) and *scn1Lab*-KD (F₂) living larval brain. Scale bar 20
 187 μm in all images. $N =$ number of larvae and $n =$ number of microglial cells. All images were
 188 acquired with a SP8 Leica laser scanning confocal equipped with a 40x/water 1.1 objective.
 189 All data are represented as the mean ± sem. p -values were determined using Mann-Whitney
 190 test. ****, $p < 0.0001$.

191 **Increased microglia-mediated brain inflammation in *scn1Lab*-KD larvae**

192 Because the microglia phenotypic changes observed in *scn1Lab*-KD larvae were strongly
193 reminiscent of those of “activated” M1-type neuroinflammatory microglia observed in various
194 neuronal disease situations, including epilepsy (Morin-Brureau *et al.*, 2018), we next evaluated
195 the neuroinflammatory profile in the brain of *scn1Lab*-KD larvae. First, we used qRT-PCR to
196 quantify the brain accumulation of transcripts encoding two key pro-inflammatory cytokines,
197 interleukin-1 β (Il1 β) and interleukin-8 (Il8), and three anti-inflammatory cytokines, interleukin-
198 10 (Il10), interleukin-4 (Il4) and transforming growth factor β -3 (Tgf β 3). Surprisingly, we did not
199 observe any significant changes, neither in the expression of pro-inflammatory markers *il1 β*
200 (WT: 1.00 \pm 0.22 vs. *scn1Lab*-KD: 1.33 \pm 0.18; $p > 0.05$) and *il8* (WT: 1.00 \pm 0.09 vs. *scn1Lab*-
201 KD: 0.93 \pm 0.11; $p > 0.05$) (**Figure 3A**), nor in that of anti-inflammatory markers *il10* (WT: 1.00
202 \pm 0.21 vs. *scn1Lab*-KD: 0.767 \pm 0.17; $p > 0.05$), *il4* (WT: 1.00 \pm 0.12 vs. *scn1Lab*-KD: 0.89 \pm
203 0.19; $p > 0.05$) and *tgf β 3* (WT: 1.00 \pm 0.04 vs. *scn1Lab*-KD: 0.876 \pm 0.08; $p > 0.05$) (**Figure**
204 **3B**). Therefore, although morphological changes seen in *scn1Lab*-KD larvae suggested pro-
205 inflammatory microglial activation, no significant increase in the expression of pro- or anti-
206 inflammatory cytokines could be detected in the brain of these individuals. It may be that in this
207 genetic model of epilepsy, levels of neuroinflammation are lower than those observed in rodent
208 pharmacological models, as also suggested by the relatively small percentage of amoeboid
209 microglia in *scn1Lab*-KD individuals (~30%). To analyze more precisely the microglial
210 expression of Il1 β in this genetic context, we generated *scn1Lab*-KD larvae also expressing
211 the Tg[*mpeg1*:mCherryF] and Tg[*il1 β* :GFP] transgenes (Nguyen-Chi *et al.*, 2015). The results
212 revealed a significant increase in the percentage of microglia expressing Il1 β (WT: 14.6 \pm 1.7
213 vs. *scn1Lab*-KD: 33.6 \pm 1.7%; $p < 0.0001$) (**Figure 3C-F**). These results confirmed an
214 increased number of activated microglial cells in *scn1Lab*-KD larvae, consistent with the
215 increased number of “amoeboid” microglia previously characterized.



216

217 **Figure 3: Study of the inflammatory profile of *scn1Lab-KD* larvae.**


218 (A) Quantification of the expression of genes encoding pro-inflammatory cytokines, *Il1β* and
 219 *Il8*, relative to that of the *tbp* gene, in the brain of control (white) and *scn1Lab-KD* (blue) larvae,
 220 aged 4 dpf. (B) Quantification of the expression of the genes encoding the anti-inflammatory
 221 cytokines, *Il10*, *Il4*, and *Tgfβ3*, relative to that of the *tbp* gene, in the brain of control (white)
 222 and *scn1Lab-KD* (blue) larvae aged 4 dpf. (C-D) Dorsal view of the periventricular stratum of
 223 control (C) and *scn1Lab-KD* (D) 4 dpf larvae, showing microglial cells (C₁, D₁), *Il1β* protein
 224 expression (C₂, D₂), as well as the superposition of the two signals (C₃, D₃). (E) Diagram of
 225 the head of a zebrafish larva with the area of interest (the periventricular stratum) framed in
 226 red. (F) Quantification of the percentage of microglial cells expressing the cytokine *Il-1β* in
 227 control larvae (*N* = 19) and *scn1Lab-KD* (*N* = 16). Scale: 10 μm. *N* = number of larvae analyzed.
 228 All images were acquired using a Leica SP8 confocal microscope, equipped with a 20x/water
 229 objective with a numerical aperture of 0.75. All graphs represent mean ± sem. The *p*-values
 230 were calculated using a Student's *t*-test. n.s., not significant; ****, *p*<0.0001.

231 **Microglia ablation increases neuronal activation in *scn1Lab-KD* larvae**

232 The phenotypic changes and *Il1β* expression observed in microglia of *scn1Lab-KD* larvae
 233 strongly suggest that a small, albeit significant, proportion of microglia, approximately 30% of

234 the cells, respond to neuronal seizures through M1-type pro-inflammatory activation. These
235 results then raised the question of whether this microglial response globally mitigates or
236 worsens subsequent activity of neuronal networks. As a first attempt to address this question,
237 we generated *scn1Lab*-KD larvae expressing the Tg[*HuC:GCaMP5G*] transgene, a sensitive
238 calcium bio-sensor (Akerboom *et al.*, 2012), and entirely devoid of microglia following
239 morpholino-mediated inactivation of the *pU.1* gene, which encodes a factor essential for proper
240 differentiation of macrophages and microglia (Rhodes *et al.*, 2005; Peri and Nüsslein-Volhard,
241 2008). As previously described (Peri and Nüsslein-Volhard, 2008), the brain of larvae injected
242 with *PU.1* morpholinos are devoid of microglia, as shown by the absence of L-plastin
243 immunostaining (**Figure 4A₂**) compared with non-injected larvae (**Figure 4A₁**). With these
244 tools, we analyzed and compared neuronal activation in WT and *scn1Lab*-KD larvae, devoid
245 or not of microglia, using calcium imaging and local field potential (LFP) recordings
246 simultaneously.

247 As previously shown (Brenet *et al.*, 2019; Liu and Baraban, 2019), when compared to WT
248 individuals, *scn1Lab*-KD larvae display a markedly increased neuronal activity as indicated by
249 the larger number of seizure-like events revealed by either calcium imaging (WT: 16.5 ± 1.0
250 vs. *scn1Lab*-KD: 32.2 ± 1.4 , $p < 0.0001$) (**Figures 4B, 4D₁**) and (**Supp. Video 5**,
251 <https://urlz.fr/jlSX>), (**Supp. Video 6**, <https://urlz.fr/jlT1>) and LFP recording (WT: 4.8 ± 1.2 vs.
252 *scn1Lab*-KD: 28.2 ± 2.4 , $p < 0.0001$) (**Figures 4C, 4E₁**). More importantly, microglia depletion
253 increased the amplitude of neuronal events in both WT and *scn1Lab*-KD larvae (**Figure 4D₂**,
254 **4E₂**) and (**Supp. Video 7**, <https://urlz.fr/jlTa>), (**Supp. Video 8**, <https://urlz.fr/jlTr>), and
255 exacerbated the number of epileptiform events in *scn1Lab*-KD individuals, suggesting that
256 microglia displayed a neuroprotective activity that was able to mitigate, at least partially,
257 neuronal hyperactivation.



258

259

260

261

262

263

264

265

266

267

268

269

270

271


Figure 4: Consequences of microglial genetic depletion on neuronal activity in the *scn1Lab* model.

(A) Schematic of the experimental setup. (B) 20 min representative calcium traces of 4 dpf control ($N = 11$), *scn1Lab*-KD ($N = 16$), control without microglia ($N = 9$) and *scn1Lab*-KD without microglia ($N = 9$) larvae (from top to bottom). (C) 20 min representative LFP traces of 4 dpf control ($N = 5$), *scn1Lab*-KD ($N = 5$), control without microglia ($N = 5$) and *scn1Lab*-KD without microglia ($N = 5$) larvae (from top to bottom). Scale bars of calcium traces: 0.05 $\Delta F/F_0$ and 1 min; of LFP traces: 0.5 mV and 1 min. (D) Quantification of calcium events, fluorescence increase greater than 0.04 $\Delta F/F_0$, frequency (D₁), and amplitude (D₂) during 1-hour recording in 4 dpf control (white) and *scn1Lab*-KD (blue) larvae. (E) Quantification of LFP events, downwards depolarization greater than 0.3 mV and lasting more than 100 ms, frequency (E₁), and amplitude (E₂) during 1-hour recording in 4 dpf control (white) and *scn1Lab*-KD (blue) larvae. $N =$ number of larvae. All data are represented as the mean \pm sem. ****, $p < 0.0001$:

272 indicates a statistically significant difference between control and *scn1Lab*-KD larvae. \$\$, $p <$
 273 0.01; \$\$\$, $p <$ 0.001; \$\$\$\$, $p <$ 0.0001: indicates a statistically significant difference between
 274 larvae with or without microglial cells. p -values were determined using two-way ANOVA with
 275 Tukey post-tests.

276 **Microglia ablation exacerbates seizure-like swimming behavior of *scn1Lab*-KD larvae**

277 It has been shown that *scn1Lab* mutant and morphant exhibit spontaneous seizure-like
 278 swimming behavior consisting of whole-body convulsions and rapid undirected movements
 279 (Scott C. Baraban, Dinday and Hortopan, 2013; Brenet *et al.*, 2019). Therefore, we questioned
 280 whether the locomotor activity of *scn1Lab*-KD larvae was dependent on microglia (**Figure 5A**).
 281 As previously shown, *scn1Lab*-KD larvae swam longer and over longer distances than WT
 282 (WT: 212 ± 11 vs. *scn1Lab*-KD: 355 ± 11 mm, $p <$ 0.0001), reflecting their neuronal
 283 hyperactivation (**Figures 5F, 5G, 5H**). Interestingly, in *scn1Lab*-KD larvae devoid of microglia,
 284 we observed a markedly increased locomotor activity compared with that observed in *scn1Lab*-
 285 KD individuals not microglia-depleted (*scn1Lab*-KD: 355 ± 11 vs. microglia-depleted *scn1Lab*-
 286 KD: 423 ± 12 mm, $p <$ 0.0001) (**Figures 5B-D**), suggesting that microglia depletion worsened
 287 the locomotor behavior of *scn1Lab*-KD larvae thus confirming that neuronal activation was
 288 exacerbated in *scn1Lab*-KD larvae lacking microglia compared to that observed in *scn1Lab*-
 289 KD individuals.



290

291 **Figure 5: Consequences of genetic ablation of microglia on the locomotor activity of**
292 ***scn1Lab*-KD larvae.**

293 (A) Diagram describing the experimental protocol. (B) Plots of distances traveled by control
294 larvae ($N = 148$), *scn1Lab*-KD ($N = 184$), controls without microglia ($N = 45$) and *scn1Lab*-KD
295 without microglia ($N = 288$) (from right to left). The swimming speed is represented according
296 to the following color code: black represents a low speed, green a medium speed, and red a
297 high speed. (C) Quantification of the total distance traveled by 4 dpf control (white) and
298 *scn1Lab*-KD (blue) larvae during the 30 minutes recording. (D) Quantification of the time spent
299 by 4 dpf control (white) and *scn1Lab*-KD (blue) larvae in a motionless position (D₁), at low (D₂),
300 medium (D₃), and high swimming speed (D₄). $N =$ number of larvae. All graphs represent the
301 average \pm sem. The p -values were calculated by a two-way ANOVA followed by a Tukey post-
302 test. ***, $p < 0,001$; ****, $p < 0,0001$: indicates a statistical difference between genotypes. \$\$\$,
303 $p < 0,001$; \$\$\$\$, $p < 0,0001$: indicate significant differences depending on the presence or
304 absence of microglia.

305 Discussion

306 A close relationship between epileptic seizures and microglia-mediated brain inflammation
307 was established long ago (Vezzani *et al.*, 2004). However, the precise response of microglia
308 to epileptic seizures and its consequences on subsequent neuronal network function have
309 been scantily studied so far, especially in *in vivo* models. Furthermore, it has not been known
310 whether seizure-induced microglia activities reduce or exacerbate neuronal network activity
311 (Lukens and Eyo, 2022). This knowledge gap has several causes, one being that microglia
312 cannot be imaged *in vivo* through the skull in rodents and most other animal species.
313 Transparent windows must be cut, involving delicate surgery and risks of brain trauma that can
314 influence the state of microglia, which are highly sensitive to disturbances in brain homeostasis
315 (He *et al.*, 2018). Zebrafish larvae offer a helpful alternative model because they are
316 transparent, enabling easy imaging of microglial cells in real-time, in a living brain and in its
317 physiological environment (Peri and Nüsslein-Volhard, 2008).

318 Another difficulty has been that most studies investigating microglia activities in rodent
319 epilepsy models have been conducted using pharmacologically-induced seizures. Those
320 chemicals can then cause extended *status epilepticus*-like activity, usually lasting several
321 hours (Ravizza *et al.*, 2008; Avignone *et al.*, 2015; Vezzani, Balosso and Ravizza, 2019;
322 Maupu *et al.*, 2021), and evoke much stronger brain inflammation than that observed in genetic
323 models, and probably human patients (Gasmi *et al.*, 2021; Maupu *et al.*, 2021; Somkhit,
324 Yanicostas and Soussi-Yanicostas, 2022). This difficulty can be overcome by using a genetic
325 epilepsy model. We report here what is, to our knowledge, the first study of the response of
326 microglial cells *in vivo* in such a model.

327 We chose an established zebrafish model of Dravet syndrome (DS), a severe epileptic
328 encephalopathy caused by a deficit in the activity of inhibitory interneurons, most commonly
329 caused by *de novo* loss-of-function mutations in the *SCN1A* gene encoding the voltage-gated
330 sodium channel NaV1.1. This zebrafish DS model is based on the loss-of-function of one of
331 the two zebrafish orthologues of the *SCN1A* gene, *scn1Lab*. Mutants and morphants *scn1Lab*
332 larvae display recurrent epileptiform seizures from 3 dpf onward, which we and others had
333 previously characterized (Scott C. Baraban, Dinday and Hortopan, 2013; Brenet *et al.*, 2019).
334 In particular, we previously showed that loss of *scn1Lab* function induced a shift in the
335 excitatory/inhibitory balance, with a decreased number of GABAergic synapses and an
336 increased number of glutamatergic ones, combined with an increased number of apoptotic
337 neurons (Brenet *et al.*, 2019).

338 In close agreement with findings in both preclinical animal models and human patients
339 (Altmann *et al.*, 2022), microglia displayed significant morphological differences in *scn1Lab*-
340 KD larvae compared to their wild-type siblings. In the mutant context, we observed a decreased

341 number of “branched” microglia and an increased percentage of microglia showing an
342 amoeboid morphology. These “amoeboid” microglia probably correspond to the previously
343 described M1-type pro-inflammatory “activated” cells observed after brain injuries or in various
344 neuronal disease situations including epilepsy (Morin-Brureau *et al.*, 2018), but also following
345 intoxication by neurotoxic compounds, such as organophosphates (Nakajima and Kohsaka,
346 2001; Somkhit, Yanicostas and Soussi-Yanicostas, 2022). Interestingly, although the disease
347 was associated with an increased number of microglia with an “activated” phenotype, the
348 proportion of “transitional” microglia was similar in the two genetic contexts, and a small
349 percentage of “resting” microglia was still observed in *scn1Lab*-KD individuals. These
350 observations highlight the complexity of the microglial response in epilepsy and, more
351 importantly, are evidence that different populations of microglial cells are present in epileptic
352 brains, each likely playing a distinct role in the pathophysiology of the disease. Although
353 increased expression of pro-inflammatory mediators has been observed both in patients with
354 different forms of epilepsy and in various animal models (Leal *et al.*, 2017; Morin-Brureau *et*
355 *al.*, 2018), other studies have shown that anti-inflammatory cytokines are also increased in the
356 epileptic brain (Benson, Manzanero and Borges, 2015). All evidence of a complex response
357 of microglia to epileptic seizures.

358 Surprisingly, and in contrast with reports in most rodent epilepsy models, qRT-PCR
359 analysis found no significant overexpression of pro-inflammatory cytokine-encoding genes,
360 *il1 β* and *il8*, in the brain of *scn1Lab*-KD individuals. This result is probably due to the moderate
361 severity of the seizures in these larvae compared with those induced by pharmacological
362 agents, such as PTZ, kainate, or DFP (Maupu *et al.*, 2021; Somkhit, Yanicostas and Soussi-
363 Yanicostas, 2022), whatever the model species. However, using the transgenic Tg[il1 β :GFP]
364 line, which enables Il1 β -expressing cells to be visualized (Nguyen-Chi *et al.*, 2015), we
365 observed a significant increase in the percentage of microglia expressing Il1 β in *scn1Lab*-KD
366 individuals compared with their WT siblings. This observation, which is in close agreement with
367 our cluster analysis, further confirmed not only the increased number of M1-like “activated”
368 microglia in *scn1Lab*-KD larvae, but also the existence of at least two distinct microglia
369 populations, with and without expression of Il1 β . However, the increased expression of il1 β
370 was probably too weak to be detected by qRT-PCR analysis of brain RNAs, highlighting the
371 differences between genetic and pharmacological epilepsy models again (Maupu *et al.*, 2021;
372 Somkhit, Yanicostas and Soussi-Yanicostas, 2022). It is also of note that studies of microglia-
373 mediated neuroinflammation in *Scn1A*^{+/-} mice yielded widely varying results. In some studies,
374 significant activation of microglial cells was observed in the prefrontal cortex and dentate gyrus,
375 combined with an increased expression of the *il1 β* and *Tnfa* genes (Satta *et al.*, 2021), while
376 in other studies, no microglia activation was detected in the hippocampus of *Scn1A*^{+/-} mice
377 associated with a lack of over-expression of pro-inflammatory mediators (Salgueiro-Pereira *et*

378 *al.*, 2019). Furthermore, Benson *et al.* (2015) showed that whereas microglia expressed both
379 pro- and anti-inflammatory mediators in the mouse pilocarpine model, only pro-inflammatory
380 mediators were overexpressed in microglia of mice exposed to kainate (Benson, Manzanero
381 and Borges, 2015). Complex alterations in microglial M1/M2 markers during the development
382 of epilepsy in two mouse models highlight the wide variety of microglial responses to seizures.

383 Genetic depletion of microglia in *scn1Lab*-KD larvae exacerbated the hyper-activity of
384 neuronal networks, as shown by the increased number of spontaneous epileptiform seizures
385 and worsening of the characteristic swirling swimming behavior. These results thus suggest
386 that microglia played a protective role in epileptic brains and mitigated neuronal activity. Like
387 ours, other studies have concluded that microglia play a beneficial role in epilepsy through
388 mitigation of neuronal activity and modulation of synaptic plasticity (Mirrione *et al.*, 2010; Li, X.
389 F. Du, *et al.*, 2012; Badimon *et al.*, 2020). In addition, Mirrione *et al.* (2010) showed that total
390 microglia ablation in adult mice led to an increased sensitivity to the pro-convulsant substance
391 pilocarpine (Mirrione *et al.*, 2010), further evidence that microglia display neuroprotective
392 functions in an epileptic context. However, preventing microglia proliferation using the selective
393 CSF1-R inhibitor GW2580 during the late stage of the epileptogenesis (but not the early stage)
394 decreased spontaneous seizures in the kainate mouse model (Di Nunzio *et al.*, 2021).

395 This work extends our understanding of the role of microglia in epilepsy. The principal
396 added value of our study is that it is the first investigation of the response of microglial cells *in*
397 *vivo* in a genetic epilepsy model. We show that epileptiform seizures rapidly induce microglia
398 reprogramming characterized by significant changes in cell shape and dynamic behavior, and
399 increased expression of pro-inflammatory cytokine IL-1 β . However, this reprogramming is
400 partial and concerns only part of the microglia, suggesting that the response of these cells to
401 seizures is complex and not limited to M1-type activation. Importantly, we also show that
402 *scn1Lab*-KD larvae entirely devoid of microglia presented an increased number of seizures,
403 with greater intensity, suggesting that microglia activity lends neuroprotection to epileptic
404 neurons. Future research will be needed to investigate how microglial cells modulate neuronal
405 activity. Indeed, modulating microglial cells activity may offer a novel therapeutic strategy of
406 great potential interest by reducing neuronal hyperactivity in epilepsies.

407 **Materials and Methods**

408 **Transgenic lines and fish maintenance**

409 Zebrafish were maintained at 26.5°C in 14 h light and 10 h dark cycles. Embryos were
410 collected by natural spawning and raised at 28.5°C in E3 medium. Developmental stages were
411 determined as hours post-fertilization (hpf) or days post-fertilization (dpf) as previously
412 described. 0.003% 1-phenyl-2-thiourea (PTU) was added at 1 dpf to avoid pigmentation.
413 The *scn1Lab*^{s552} line has been previously described (Schoonheim *et al.*, 2010) and was
414 generously provided by the laboratory of Dr. Herwig Baier. Calcium imaging was performed
415 using Tg[*Huc*: GCaMP5G] (Akerboom *et al.*, 2012). Microglia were visualized using Tg[*mpeg1*:
416 mCherryF] (Ellett *et al.*, 2011) and cytokine Il1 β expression using Tg[*il1 β* : GFP] (Nguyen-Chi
417 *et al.*, 2015).

418 All the animal experiments described were conducted at the French National Institute of Health
419 and Medical Research (INSERM), UMR 1141, Paris, in compliance with European Union
420 guidelines for the handling of laboratory animals
421 (http://ec.europa.eu/environment/chemicals/lab_animals/home_en.htm). They were approved
422 by the Direction Départementale de la Protection des Populations de Paris and the French
423 Animal Ethics Committee under reference No. 2012-15/676-0069.

424 **Morpholino knockdown**

425 The following morpholinos, obtained from Gene Tools (Philomath, Oregon, USA), were used
426 in this study: 5'-CTGAGCAGCCATATTGACATCCTGC-3' was used at 0.62 mM to block the
427 *scn1Lab* zebrafish mRNA transcription; 5'-GATATACTGATACTCCATTGGTGGT-3' was used
428 at 0.88 mM to block the *PU.1* zebrafish mRNA transcription. These morpholinos were injected
429 with 0.03 mM rhodamine B dextran and 0.1 mM KCl into embryos at stage 1–2 cells.

430 **Microglia morphology**

431 4 dpf Tg[*mpeg1*:mCherryF] larvae were paralyzed using 300 μ M pancuronium bromide (Sigma
432 Aldrich, Saint-Louis, Missouri, USA) and agar-immobilized in the center of a 35 mm glass-
433 bottom dish. A 100 μ m stack of the larval living optic tectum was acquired at 1024 \times 1024-pixel
434 resolution using a Leica SP8 laser scanning confocal microscope equipped with a 20 \times /0.75
435 multi-immersion objective. Images were processed using AutoQuant X3 (Media cybernetic,
436 Rockville, Maryland, USA) and Fiji ImageJ (NIH) software. Microglial cells' surface area,
437 volume and sphericity were quantified using Imaris MeasurementPro (Oxford Instruments,
438 Abingdon, UK). The number and length of microglial processes and their Sholl analysis were
439 determined using Imaris Filament Tracer (Oxford Instruments, Abingdon, UK).

440 **Clustering of microglial cells**

441 Cluster analysis was performed using sphericity (S), number of processes (NP), total
442 processes length (TL), surface area (A), and volume (V) of microglial cells. Microglial cells with
443 at least three of the following features: sphericity less than 0.5, number of processes greater
444 than 7, total processes length greater than 140 μm , and a surface area greater than 2400 μm^2
445 were classified as “branched” microglia. Conversely, microglial cells with at least three of the
446 following features: sphericity greater than 0.7, number of processes less than 3, total
447 processes length less than 60 μm , and surface area less than 1500 μm^2 were classified as
448 “amoeboid” microglia. Microglial cells with fewer than three “branched” or “amoeboid”
449 characteristics were classified as “transitional” microglia.

450 **RNA isolation and quantitative RT-PCR**

451 For RNA isolation, whole larvae or dissected brains were homogenized using a syringe
452 equipped with a 26G needle (10 brains per sample) using the RNA XS Plus kit (Macherey
453 Nagel, Düren, Germany). Following RNA quantification with a Nanodrop 2000
454 (ThermoScientific, Waltham, Massachusetts, USA) and RNA integrity assessment using
455 denaturing gel electrophoresis, total RNAs (1 μg) were reverse transcribed into cDNAs using
456 the iScript cDNA Synthesis Kit (Bio-Rad, Germany) and qPCRs were performed using iQ
457 SYBR Green Supermix (Bio-Rad, Germany). Samples were run in triplicate and expression
458 levels of the studied genes were normalized to that of the *tbp* gene. The primers (Eurofins
459 Genomics, Ebersberg, Germany) used are listed in Supplementary Table 1.

460 **Microglial dynamics**

461 4 dpf pancuronium bromide-paralyzed Tg[mpeg1:mCherryF] larvae were agar-immobilized in
462 the center of a 35 mm glass-bottom dish. A 42 μm stack of the larval living half optic tectum
463 was acquired at 1024 \times 512-pixel resolution every 40 s for 1 h using a Leica SP8 laser scanning
464 confocal microscope equipped with 40 \times /1.1 water objective (Leica, Wetzlar, Germany). Videos
465 were processed using ImageJ software. Microglial cell body displacement, distance traveled
466 between the first and the last frame, and microglial cell body speed displacement were
467 quantified using Imaris MeasurementPro.

468 **Calcium imaging**

469 For quantification, 4 dpf Tg[Huc:GCaMP5G] larvae were paralyzed using pancuronium
470 bromide, agar-immobilized in the center of a recording chamber, and placed under a Leica
471 SP8 laser scanning confocal microscope equipped with a 20 \times /0.75 multi-immersion objective.
472 A single focal plane of the optic tectum was captured at a high frequency for 40 minutes. The
473 mean grey value of each frame was measured using ImageJ software, and fluorescence
474 variation ($\Delta F/F_0$) was calculated using Excel (Microsoft, Redmond, Washington, USA) by

475 subtracting the mean fluorescence intensity of all frames from the fluorescence intensity of a
476 frame of interest, then normalizing this difference by the mean fluorescence intensity of all
477 frames. The fluorescence drift during recording was corrected by subtracting the background
478 intensity of the surrounding frame. Calcium events were defined as any fluorescence increase
479 greater than $0.04 \Delta F/F_0$.

480 For movie illustration (Supp. Video 5, 6, 7, 8), larvae were paralyzed and immobilized as
481 described above. Calcium transient in a single focal plane of the optic tectum of larvae were
482 captured for 5 min, at 5 Hz, using a Yokogawa CSU-X1 spinning disk confocal microscope
483 (Yokogawa, Tokyo, Japan) equipped with a LD LCI Plan-Apochromat 25x/0.8 DIC Imm Korr
484 (UV) objective (Zeiss, Oberkochen, Germany).

485 **Local field potential recording**

486 Local field potential recording was performed as described in Brenet et al., 2019.

487 Briefly, 4 dpf larvae were paralyzed using pancuronium bromide and agar-immobilized in the
488 center of a recording chamber. A glass electrode filled with artificial cerebrospinal fluid was
489 placed in the right neuropil of the optic tectum. Neuronal activity was recorded for 1 h in current
490 clamp mode at 10 μ s sampling interval, amplified with a digital gain of 10, and filtered through
491 a 0.1 Hz high-pass filter and 1 kHz low-pass filter. Recordings were analyzed using Clampfit
492 software (Molecular Devices, San Jose, California, USA). Every downward membrane
493 potential variation under -0.3 mV amplitude and lasting more than 100 ms was defined as an
494 event.

495 **Locomotor activity**

496 Larval locomotor activity was assessed using an infrared automated tracking device
497 (ZebraBox), controlled by ZebraLab software (ViewPoint, Lyon, France). First, 4 dpf larvae
498 were individually spread in a 96-well plate in 200 μ L E3 medium. The plate was then placed
499 inside the ZebraBox recording chamber in the dark for 30 minutes of habituation after which
500 larvae were tracked for 30 min divided into one-minute integration time. The animal color was
501 set to dark and detection sensitivity to 12 for tracking. Besides the total distance swum by the
502 larvae, we also recorded the number of times that the larvae were immobile, in low-speed,
503 medium-speed, and high-speed movements, together with the duration of the events. The
504 inactive speed threshold was set at 4 mm and the high-speed threshold at 8 mm. Each
505 experiment replicates comprised at least 16 larvae per condition and was completed at least
506 three times.

507 **Data analysis**

508 Data were analyzed and plotted using R-studio 1.2.5. (Posit, Boston, Massachusetts, USA).
509 Data are presented as mean \pm sem. Statistical analysis of Figures 1 and 2 was performed

510 using the Mann-Whitney test, if data did not follow a normal distribution, or Student's unpaired
511 *t*-test with or without Welch's correction depending on the variance difference. Two-way
512 ANOVA with Tukey post-test was used to analyze data in Figures 3, 4, and 5.

513 **Conflict of Interest**

514 The authors declare that the research was conducted in the absence of any commercial or
515 financial relationships that could be construed as a potential conflict of interest.

516 **Author Contributions:** AB performed experiments and contributed to the analyses and
517 interpretation of the data. JS performed qRT-PCR. ZC helped with imaging experiments. SC
518 & EK helped with LFP experiments. CY co-led the project and contributed to the writing of the
519 article. NSY led the project, designed the experimental research, and contributed to
520 interpreting the data and writing the manuscript. All authors have read and agreed to the
521 published version of the manuscript.

522 **Funding:** This work was supported by the Institut National de la Santé et de la Recherche
523 Médicale (INSERM), and the National Centre for Scientific Research (CNRS). Funding
524 sources had no involvement in the study design, collection, analysis, or interpretation of data,
525 nor in the decision to publish.

526 **Acknowledgments:** We thank Francesca Peri (University of Zurich, Switzerland) for providing
527 us with the Tg(p2y12:P2Y12-GFP) transgenic line and George Lutfalla (University of
528 Montpellier, France) for providing us with the Tg(il1 β :GFP). We also thank Christiane Romain
529 and Olivier Bar (INSERM UMR 1141) for their technical assistance.

530 **Conflicts of Interest:** The authors declare no conflict of interest.

531 **Supplementary figures**

532 **Supplementary video 1:** 3D reconstruction of a representative microglia from a control
533 brain's larvae (**Figure 1A**). 3D images were generated using Imaris software (Biplane Inc.,
534 Version 9.5.0). (Link: <https://urlz.fr/iPxZ>).

535 **Supplementary video 2:** 3D reconstruction of a representative microglia from a *scn1Lab*-KD
536 brain's larvae (**Figure 1B**). 3D images were generated using Imaris software (Biplane Inc.,
537 Version 9.5.0). (Link: <https://urlz.fr/iPxP>).

538 **Supplementary video 3:** Time-lapse of 4 dpf control larvae dorsal view showing microglial
539 displacement and processes dynamic (**Figure 2A**). Interval between frames: 39 s. Video
540 played at x6. Microglial tracking displacement was performed using Imaris software (Biplane
541 Inc., Version 9.5.0). (Link: <https://urlz.fr/iOIz>).

542 **Supplementary video 4:** Time-lapse of 4 dpf *scn1Lab* larvae dorsal view showing microglial
 543 displacement and processes dynamic (**Figure 2B**). Interval between frames: 39 s. Video
 544 played at x6. Microglial tracking displacement was performed using Imaris software (Biplane
 545 Inc., Version 9.5.0). (Link: <https://urlz.fr/iOIA>).

546 **Supplementary Video 5:** Representative time-lapse recording of calcium activity in the optic
 547 tectum of control larvae (**Figure 4B – control with microglia**). Interval between frames: 200 ms.
 548 Video played at x5.

549 **Supplementary Video 6:** Representative time-lapse recording of calcium activity in the optic
 550 tectum of *scn1Lab*-KD larvae (**Figure 4B – *scn1Lab*-KD with microglia**). Interval between
 551 frames: 200 ms. Video played at x5.


552 **Supplementary Video 7:** Representative time-lapse recording of calcium activity in the optic
 553 tectum of control larvae without microglia (**Figure 4B – control w/o microglia**). Interval between
 554 frames: 200 ms. Video played at x5.

555 **Supplementary Video 8:** Representative time-lapse recording of calcium activity in the optic
 556 tectum of *scn1Lab*-KD larvae without microglia (**Figure 4B – *scn1Lab*-KD w/o microglia**).
 557 Interval between frames: 200 ms. Video played at x5.

558 **Supplementary table**

<i>il-1β</i>	Forward	5'-CTT AAC CAG CTC TGA AAT GAT G-3'
	Reverse	5'-TGT CGC ATC TGT AGC TCA TTG-3'
<i>il-8</i>	Forward	5'-TGA CCA TCA TTG AAG GAA TGA G-3'
	Reverse	5'-CAT CAA GGT GGC AAT GAT CTC-3'
<i>tnf-α</i>	Forward	5'-TCA CGC TCC ATA AGA CCC AG-3'
	Reverse	5'-GAT GTG CAA AGA CAC CTG GC-3'
<i>il-4</i>	Forward	5'-GAG ACA GGA CAC TAC TCT AAG-3'
	Reverse	5'-GTT TCC AGT CCC GGT ATA TG-3'
<i>il-10</i>	Forward	5'-AAC GAG ATC CTG CAT TTC TAC-3'
	Reverse	5'-CCT CTT GCA TTT CAC CAT AT-3'
<i>tgf-β3</i>	Forward	5'-AAA ACG CCA GCA ACC TGT TC-3'
	Reverse	5'-CCT CAA CGT CCA TCC CTC TG-3'

559



- 563 Akerboom, J. *et al.* (2012) 'Optimization of a GCaMP calcium indicator for neural activity
564 imaging', *Journal of Neuroscience*. Society for Neuroscience, 32(40), pp. 13819–13840. doi:
565 10.1523/JNEUROSCI.2601-12.2012.
- 566 Altmann, A. *et al.* (2022) 'A systems-level analysis highlights microglial activation as a
567 modifying factor in common epilepsies', *Neuropathology and Applied Neurobiology*, 48(1).
568 doi: 10.1111/nan.12758.
- 569 Andoh, M., Ikegaya, Y. and Koyama, R. (2019) 'Synaptic Pruning by Microglia in Epilepsy',
570 *Journal of Clinical Medicine*. MDPI AG, 8(12), p. 2170. doi: 10.3390/jcm8122170.
- 571 Avignone, E. *et al.* (2015) 'Altered morphological dynamics of activated microglia after
572 induction of status epilepticus.', *Journal of Neuroinflammation*. Journal of Neuroinflammation,
573 12(1), p. 202. doi: 10.1186/s12974-015-0421-6.
- 574 Badimon, A. *et al.* (2020) 'Negative feedback control of neuronal activity by microglia',
575 *Nature*. Nature Research, 586(7829), pp. 417–423. doi: 10.1038/s41586-020-2777-8.
- 576 Baraban, Scott C, Dinday, M. T. and Hortopan, G. A. (2013) 'Drug screening in Scn1a
577 zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.', *Nature*
578 *communications*, 4, p. 2410. doi: 10.1038/ncomms3410.
- 579 Baraban, Scott C., Dinday, M. T. and Hortopan, G. A. (2013) 'Drug screening in Scn1a
580 zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment', *Nature*
581 *Communications*. Nature Publishing Group, 4(1), p. 2410. doi: 10.1038/ncomms3410.
- 582 Benson, M. J., Manzanero, S. and Borges, K. (2015) 'Complex alterations in microglial
583 M1/M2 markers during the development of epilepsy in two mouse models', *Epilepsia*.
584 Blackwell Publishing Inc., 56(6), pp. 895–905. doi: 10.1111/epi.12960.
- 585 Boer, K. *et al.* (2008) 'Inflammatory processes in cortical tubers and subependymal giant cell
586 tumors of tuberous sclerosis complex', *Epilepsy Research*. Elsevier, 78(1), pp. 7–21. doi:
587 10.1016/j.epilepsyres.2007.10.002.
- 588 Brenet, A. *et al.* (2019) 'Defective Excitatory/Inhibitory Synaptic Balance and Increased
589 Neuron Apoptosis in a Zebrafish Model of Dravet Syndrome', *Cells*. MDPI AG, 8(10), p.
590 1199. doi: 10.3390/cells8101199.
- 591 Brunklaus, A., Dorris, L. and Zuberi, S. M. (2011) 'Comorbidities and predictors of health-
592 related quality of life in Dravet syndrome', *Epilepsia*. Epilepsia, 52(8), pp. 1476–1482.
593 Available at: <https://pubmed.ncbi.nlm.nih.gov/21668444/> (Accessed: 24 April 2021).
- 594 Claes, L. *et al.* (2001) 'De Novo Mutations in the Sodium-Channel Gene SCN1A Cause
595 Severe Myoclonic Epilepsy of Infancy', *Am. J. Hum. Genet*, 68, pp. 1327–1332. doi:
596 10.1086/320609.
- 597 Dravet, C. (2011) 'Dravet syndrome history', *Developmental Medicine and Child Neurology*.
598 *Dev Med Child Neurol*, pp. 1–6. doi: 10.1111/j.1469-8749.2011.03964.x.
- 599 Ellett, F. *et al.* (2011) 'mpeg1 promoter transgenes direct macrophage-lineage expression in
600 zebrafish', *Blood*. The American Society of Hematology, 117(4), p. e49. doi: 10.1182/blood-
601 2010-10-314120.
- 602 Eyo, U. B. *et al.* (2014) 'Neuronal Hyperactivity Recruits Microglial Processes via Neuronal
603 NMDA Receptors and Microglial P2Y12 Receptors after Status Epilepticus', *Journal of*
604 *Neuroscience*, 34(32), pp. 10528–10540. doi: 10.1523/JNEUROSCI.0416-14.2014.
- 605 Fisher, R. S. *et al.* (2014) 'ILAE Official Report: A practical clinical definition of epilepsy',
606 *Epilepsia*. Blackwell Publishing Inc., 55(4), pp. 475–482. doi: 10.1111/epi.12550.
- 607 Fisher, R. S. (2015) 'Redefining epilepsy', *Current Opinion in Neurology*, 28(2), pp. 130–135.
608 doi: 10.1097/WCO.000000000000174.
- 609 Gasmi, N. *et al.* (2021) 'Low grade inflammation in the epileptic hippocampus contrasts with
610 explosive inflammation occurring in the acute phase following status epilepticus in rats:
611 translation to patients with epilepsy', *bioRxiv*. Cold Spring Harbor Laboratory, p.
612 2021.03.25.436701. doi: 10.1101/2021.03.25.436701.
- 613 Hassan-Abdi, R. *et al.* (2019) 'Neurons Expressing Pathological Tau Protein Trigger
614 Dramatic Changes in Microglial Morphology and Dynamics', *Frontiers in Neuroscience*.
615 Frontiers Media S.A., 13. doi: 10.3389/fnins.2019.01199.

616 He, Y. *et al.* (2018) 'RNA sequencing analysis reveals quiescent microglia isolation methods
617 from postnatal mouse brains and limitations of BV2 cells', *Journal of Neuroinflammation*,
618 15(1). doi: 10.1186/s12974-018-1195-4.

619 Kwan, P., Schachter, S. C. and Brodie, M. J. (2011) 'Drug-Resistant Epilepsy', *New England*
620 *Journal of Medicine*, 365(23), pp. 2238–2240. doi: 10.1056/NEJMC1111683.

621 Leal, B. *et al.* (2017) 'Brain expression of inflammatory mediators in Mesial Temporal Lobe
622 Epilepsy patients', *Journal of Neuroimmunology*, 313, pp. 82–88. doi:
623 10.1016/j.jneuroim.2017.10.014.

624 Li, Y., Du, X., *et al.* (2012) 'Reciprocal Regulation between Resting Microglial Dynamics and
625 Neuronal Activity In Vivo', *Developmental Cell*, 23(6), pp. 1189–1202. doi:
626 10.1016/j.devcel.2012.10.027.

627 Li, Y., Du, X. F., *et al.* (2012) 'Reciprocal Regulation between Resting Microglial Dynamics
628 and Neuronal Activity In Vivo', *Developmental Cell*. Cell Press, 23(6), pp. 1189–1202. doi:
629 10.1016/j.devcel.2012.10.027.

630 Liu, J. and Baraban, S. C. (2019) 'Network properties revealed during multi-scale calcium
631 imaging of seizure activity in Zebrafish', *eNeuro*. Society for Neuroscience, 6(1). doi:
632 10.1523/ENEURO.0041-19.2019.

633 Lukens, J. R. and Eyo, U. B. (2022) 'Microglia and Neurodevelopmental Disorders', *Annual*
634 *Review of Neuroscience*, 45(1). doi: 10.1146/annurev-neuro-110920-023056.

635 Marxer, C. A. *et al.* (2021) 'A review of the evidence on the risk of congenital malformations
636 and neurodevelopmental disorders in association with antiseizure medications during
637 pregnancy', *Expert Opinion on Drug Safety*, 20(12), pp. 1487–1499. doi:
638 10.1080/14740338.2021.1943355.

639 Maupu, C. *et al.* (2021) 'Diisopropylfluorophosphate-induced status epilepticus drives
640 complex glial cell phenotypes in adult male mice', *Neurobiology of Disease*, 152. doi:
641 10.1016/j.nbd.2021.105276.

642 Mildner, A. (2017) 'Ghosts in the shell: Identification of microglia in the human central
643 nervous system by p2y12 receptor', *Neural Regeneration Research*, pp. 570–571. doi:
644 10.4103/1673-5374.205090.

645 Mirrione, M. M. *et al.* (2010) 'Microglial ablation and lipopolysaccharide preconditioning
646 affects pilocarpine-induced seizures in mice', *Neurobiology of Disease*. Neurobiol Dis, 39(1),
647 pp. 85–97. doi: 10.1016/j.nbd.2010.04.001.

648 Morin-Brureau, M. *et al.* (2018) 'Microglial phenotypes in the human epileptic temporal lobe',
649 *Brain*, 141, pp. 3343–3360. doi: 10.1016/0038-1098(79)91043-3.

650 Nakajima, K. and Kohsaka, S. (2001) 'Microglia: Activation and their significance in the
651 central nervous system', *Journal of Biochemistry*. Oxford University Press, pp. 169–175. doi:
652 10.1093/oxfordjournals.jbchem.a002969.

653 Nguyen-Chi, M. *et al.* (2015) 'Identification of polarized macrophage subsets in zebrafish',
654 *eLife*. eLife Sciences Publications Ltd, 4(JULY 2015). doi: 10.7554/eLife.07288.

655 Di Nunzio, M. *et al.* (2021) 'Microglia proliferation plays distinct roles in acquired epilepsy
656 depending on disease stages', *Epilepsia*, 62(8), pp. 1931–1945. doi: 10.1111/epi.16956.

657 Peri, F. and Nüsslein-Volhard, C. (2008) 'Live Imaging of Neuronal Degradation by Microglia
658 Reveals a Role for v0-ATPase a1 in Phagosomal Fusion In Vivo', *Cell*. Elsevier B.V., 133(5),
659 pp. 916–927. doi: 10.1016/j.cell.2008.04.037.

660 Rana, A. and Musto, A. E. (2018) 'The role of inflammation in the development of epilepsy',
661 *Journal of Neuroinflammation*. BioMed Central Ltd. doi: 10.1186/s12974-018-1192-7.

662 Ravizza, T. *et al.* (2008) 'Innate and adaptive immunity during epileptogenesis and
663 spontaneous seizures: Evidence from experimental models and human temporal lobe
664 epilepsy', *Neurobiology of Disease*. Academic Press, 29(1), pp. 142–160. doi:
665 10.1016/j.nbd.2007.08.012.

666 Rhodes, J. *et al.* (2005) 'Interplay of pu.1 and Gata1 determines myelo-erythroid progenitor
667 cell fate in zebrafish', *Developmental Cell*, 8(1), pp. 97–108. doi:
668 10.1016/j.devcel.2004.11.014.

669 Salgueiro-Pereira, A. R. *et al.* (2019) 'A two-hit story: Seizures and genetic mutation
670 interaction sets phenotype severity in SCN1A epilepsies', *Neurobiology of Disease*.

671 Academic Press Inc., 125, pp. 31–44. doi: 10.1016/j.nbd.2019.01.006.
672 Satta, V. *et al.* (2021) 'Neuropathological Characterization of a Dravet Syndrome Knock-In
673 Mouse Model Useful for Investigating Cannabinoid Treatments', *Frontiers in Molecular*
674 *Neuroscience*. Frontiers Media S.A., 13, p. 602801. doi: 10.3389/fnmol.2020.602801.
675 Schoonheim, P. J. *et al.* (2010) 'Optogenetic localization and genetic perturbation of
676 saccade-generating neurons in Zebrafish', *Journal of Neuroscience*, 30(20), pp. 7111–7120.
677 doi: 10.1523/JNEUROSCI.5193-09.2010.
678 Sieger, D. *et al.* (2012) 'Long-Range Ca²⁺ Waves Transmit Brain-Damage Signals to
679 Microglia', *Developmental Cell*. Dev Cell, 22(6), pp. 1138–1148. doi:
680 10.1016/j.devcel.2012.04.012.
681 Somkhit, J., Yanicostas, C. and Soussi-Yanicostas, N. (2022) 'Microglia Remodelling and
682 Neuroinflammation Parallel Neuronal Hyperactivation Following Acute Organophosphate
683 Poisoning', *International Journal of Molecular Sciences*, 23(15). doi: 10.3390/ijms23158240.
684 Stafstrom, C. E. and Carmant, L. (2015) 'Seizures and epilepsy: An overview for
685 neuroscientists', *Cold Spring Harbor Perspectives in Biology*, 7(5), pp. 1–19. doi:
686 10.1101/cshperspect.a022426.
687 Thurman, D. J. *et al.* (2011) 'Standards for epidemiologic studies and surveillance of
688 epilepsy', *Epilepsia*, 52(SUPPL. 7), pp. 2–26. doi: 10.1111/j.1528-1167.2011.03121.x.
689 Travnickova, J. *et al.* (2015) 'Primitive macrophages control HSPC mobilization and definitive
690 haematopoiesis', *Nature Communications*, 6, pp. 1–9. doi: 10.1038/ncomms7227.
691 Vezzani, A. *et al.* (1999) 'Interleukin-1 β immunoreactivity and microglia are enhanced in the
692 rat hippocampus by focal kainate application: Functional evidence for enhancement of
693 electrographic seizures', *Journal of Neuroscience*, 19(12), pp. 5054–5065. doi:
694 10.1523/jneurosci.19-12-05054.1999.
695 Vezzani, A. *et al.* (2004) 'Functional role of proinflammatory and anti-inflammatory cytokines
696 in seizures', *Advances in Experimental Medicine and Biology*, 548, pp. 123–133. doi:
697 10.1007/978-1-4757-6376-8_10.
698 Vezzani, A. *et al.* (2008) 'Glia as a source of cytokines: Implications for neuronal excitability
699 and survival', *Epilepsia*. John Wiley & Sons, Ltd, 49(SUPPL. 2), pp. 24–32. doi:
700 10.1111/j.1528-1167.2008.01490.x.
701 Vezzani, A. (2013) 'Fetal brain inflammation may prime hyperexcitability and behavioral
702 dysfunction later in life', *Annals of Neurology*, 74(1), pp. 1–3. doi: 10.1002/ana.23930.
703 Vezzani, A., Balosso, S. and Ravizza, T. (2019) 'Neuroinflammatory pathways as treatment
704 targets and biomarkers in epilepsy', *Nature Reviews Neurology*. Nature Publishing Group,
705 pp. 459–472. doi: 10.1038/s41582-019-0217-x.
706 Vinet, J. *et al.* (2012) 'Neuroprotective function for ramified microglia in hippocampal
707 excitotoxicity', *Journal of Neuroinflammation*. BioMed Central, 9. doi: 10.1186/1742-2094-9-
708 27.
709 Woodburn, S. C., Bollinger, J. L. and Wohleb, E. S. (2021) 'The semantics of microglia
710 activation: neuroinflammation, homeostasis, and stress', *Journal of Neuroinflammation*,
711 18(1), p. 258. doi: 10.1186/s12974-021-02309-6.
712 World Health Organization (2019) *Epilepsy*.
713 Wu, Y. W. *et al.* (2015) 'Incidence of dravet syndrome in a US population', *Pediatrics*.
714 American Academy of Pediatrics, 136(5), pp. e1310–e1315. doi: 10.1542/peds.2015-1807.
715 Xue-Ping, W. *et al.* (2019) 'Risk factors for drug-resistant epilepsy: A systematic review and
716 meta-analysis', *Medicine (United States)*, 98(30), p. e16402. doi:
717 10.1097/MD.00000000000016402.
718 Zhang, Y. *et al.* (2015) 'Pharmacological Characterization of an Antisense Knockdown
719 Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin
720 Agonist Fenfluramine', *PLOS ONE*. Edited by Y. Herault. Public Library of Science, 10(5), p.
721 e0125898. doi: 10.1371/journal.pone.0125898.
722
723